Boehringer Ingelheim Venture Fund

Investor type Corporate Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 72
Average round size
The average size of a deal this fund participated in
Portfolio companies 44
Rounds per year 6.00
Lead investments 21
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 8
Key employees 7
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Life Science

Boehringer Ingelheim Venture Fund appeared to be the VC, which was created in 1973. The main office of represented VC is situated in the Ingelheim Am Rhein. The company was established in Europe in Germany. Boehringer Ingelheim Venture Fund appeared to be a CVC structure as part of the corporation.

The overall number of key employees were 7.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Boehringer Ingelheim Venture Fund, startups are often financed by High-Tech Gru00fcnderfonds, Forbion Capital Partners, BioMedPartners. The meaningful sponsors for the fund in investment in the same round are BioMedPartners, Forbion Capital Partners, Takeda Ventures. In the next rounds fund is usually obtained by High-Tech Gru00fcnderfonds, Forbion Capital Partners, BioMedPartners.

Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 27 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2016. The higher amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Boehringer Ingelheim Venture Fund works on 12 percentage points less the average amount of lead investments.

Among the most popular fund investment industries, there are Therapeutics, Robotics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Promethera Biosciences, Wellth, Tacalyx. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Boehringer Ingelheim Venture Fund:
Typical Co-investors
Boehringer Ingelheim Venture Fund is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Boehringer Ingelheim Venture Fund:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Germany
Funds with similar focus located in Germany:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Artificial Intelligence
Machine Learning
Medical Device
$21M16 Dec 2021 Oxford, England, United Kingdom

OncoMyx Therapeutics

Health Care
$50M08 Dec 2021 Tempe, Arizona, United States

Asgard Therapeutics

$7M09 Nov 2021 Lund, Skane Lan, Sweden

Optina Diagnostics

Medical Device
$19M28 Oct 2021 Montreal, Quebec, Canada

Abalos Therapeutics

$36M14 Oct 2021 Essen, North Rhine-Westphalia, Germany

Topas Therapeutics

Advanced Materials
Chemical Engineering
$21M29 Jul 2021 Germany, Baden-Württemberg, Germany


Health Care
Medical Device
$14M14 Jul 2021 Berlin, Berlin, Germany


Artificial Intelligence
Health Care
Machine Learning
$12M23 Jun 2021 California, United States


$24M18 Jun 2021 Singapore, Central Region, Singapore
Dopavision Raises €12M in Series A Funding

– Dopavision, a Berlin, Germany-based company focused on development of digital therapeutics, raised €12M in Series A funding.
– The round was led by Seventure Partners with participation from Novartis Pharmaceuticals, Boehringer Ingelheim Venture Fund and Ababax Health.
– The new investment will be used for the clinical development of MyopiaX, its lead product in childhood myopia, activities to provide innovative digital treatments for children leveraging games, educational or cognitive training applications, and potentially broaden its pipeline to new indications.

Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines

– Delonix Bioworks has closed a $14m Series Seed financing to accelerate the development of its innovative synthetic vaccines.
– The financing was led by Boehringer Ingelheim Venture Fund and IDG Capital with participation from ZhenFund and an undisclosed investor.
– The financing will be used to accelerate the building of synthetic biology vaccine platforms and advance pipelines of synthetic vaccines to clinical trials.
– Delonix is working on innovative synthetic biology approaches to develop the next generation medical solutions to address global public health challenges.
– Current lead programs target anti-microbial resistance (AMR).


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Boehringer Ingelheim Venture Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: